Exploring potential partnerships and strategic opportunities for the Company’s stem cell therapy program in Alzheimer’s diseaseAlzheimer’s disease development program with positive data in successful Phase 1 and Phase 2a clinical trialsClear regulatory pathway following positive Type B meeting with U.S. FDAFDA has granted laromestrocel both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s disease MIAMI, Sept. 22, 2025 (GLOBE NEWSWIRE) ...